<?xml version="1.0" encoding="UTF-8"?>
<ref id="B77-pharmaceuticals-12-00101">
 <label>77.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Yuan</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Chan</surname>
    <given-names>J.F.</given-names>
   </name>
   <name>
    <surname>den-Haan</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Chik</surname>
    <given-names>K.K.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>A.J.</given-names>
   </name>
   <name>
    <surname>Chan</surname>
    <given-names>C.C.</given-names>
   </name>
   <name>
    <surname>Poon</surname>
    <given-names>V.K.</given-names>
   </name>
   <name>
    <surname>Yip</surname>
    <given-names>C.C.</given-names>
   </name>
   <name>
    <surname>Mak</surname>
    <given-names>W.W.</given-names>
   </name>
   <name>
    <surname>Zhu</surname>
    <given-names>Z.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo</article-title>
  <source>Antivir. Res.</source>
  <year>2017</year>
  <volume>145</volume>
  <fpage>33</fpage>
  <lpage>43</lpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.07.007</pub-id>
  <?supplied-pmid 28712942?>
  <pub-id pub-id-type="pmid">28712942</pub-id>
 </element-citation>
</ref>
